Bone Morphogenic Protein Signaling Pathways in Uterine Biology

子宫生物学中的骨形态发生蛋白信号通路

基本信息

  • 批准号:
    8692428
  • 负责人:
  • 金额:
    $ 38.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1994
  • 资助国家:
    美国
  • 起止时间:
    1994-08-17 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The transforming growth factor 2 (TGF2) superfamily, the largest family of secreted proteins in mammals, includes the bone morphogenetic proteins (BMPs), actives, and myostatin. These ligands signal through a heteromeric complex of type 1 and type 2 serine/threonine kinase receptors. Ligand-induced dimerization of these receptors leads to phosphorylation of receptor-regulated SMAD proteins, which translocate to the nucleus with SMAD4 to regulate gene expression. These signaling pathways have been implicated in many pathophysiologic processes. For example, at the end of the first trimester, activin A levels are elevated in women who will eventually develop preeclampsia, and the BMP/activin/myostatin type 2 receptor, ACVR2A, has been identified as a candidate maternal susceptibility gene for preeclampsia. With the support of this grant that started in 1994, we have generated and analyzed mice with mutations in activin subunits, a ligand binding protein (follistatin), a downstream receptor-binding protein (FKBP12), several SMADs, and multiple BMP/activin/myostatin receptors. The phenotypes of our genetic models range from neonatal lethality to infertility to cancer. These models have been indispensable for deciphering TGF2 superfamily signaling pathways in the gonads and modeling clinical reproductive diseases including infertility, premature ovarian failure, and ovarian and testicular cancer. These HD32067-supported studies have resulted in 43 papers published during the current grant period and 87 publications overall including high impact papers in Nature, Nature Genetics, Nature Medicine, Science, Genes and Development, and Developmental Cell. The overall goals of this R01 renewal will be to follow-up these studies by analyzing the unique and redundant roles of the type 1 and type 2 receptors in BMP signaling in the uterus and identifying new agents for inhibiting and/or mimicking the functions of BMPs, activins and myostatin in uterine, ovarian, muscle, and bone physiology. The Specific Aims of these proposed studies are: 1) Define the BMP receptor pathways in implantation and post- implantation uterine biology, and 2) Identify and synthesize small molecule BMP receptor-specific antagonists and agonists. These proposed studies will allow us to genetically place TGF2 superfamily ligands, receptors, and downstream SMADs into biological pathways in the female reproductive tract, and identify and synthesize compounds for future treatments of human reproductive and non-reproductive diseases.
描述(由申请人提供):哺乳动物中最大的分泌蛋白质家族的转化生长因子2(TGF2)包括骨形态发生蛋白(BMP),活性物和肌生抑素。这些配体通过1型和2型丝氨酸/苏氨酸激酶受体的异质体复合物发出信号。这些受体的配体诱导的二聚化导致受体调节的Smad蛋白的磷酸化,后者用Smad4转移到细胞核中以调节基因表达。这些信号通路已与许多病理生理过程有关。例如,在头三个月结束时,最终将发展先兆子痫的女性中,激活素A水平升高,而BMP/Activin/Myostatin 2型受体ACVR2A已被鉴定为候选孕妇对子痫的候选母体易感基因。在始于1994年的这笔赠款的支持下,我们已经在激活素亚基中产生了和分析了小鼠,该突变是一种配体结合蛋白(Follistatin),下游受体结合蛋白(FKBP12),几种SMADS和多个BMP/激活素/肌蛋白蛋白受体。我们遗传模型的表型从新生儿致死性到不育,再到癌症。这些模型对于在性腺中解解TGF2超家族信号通路和对临床生殖疾病(包括不育,早产卵巢衰竭以及卵巢癌和卵巢癌)进行建模是必不可少的。这些HD32067支持的研究导致了当前赠款期间发表的43篇论文,总体上有87个出版物,包括自然,自然遗传学,自然医学,科学,基因和发展以及发育细胞的高影响力论文。该R01更新的总体目标将是通过分析子宫中BMP信号中1型和2型受体的独特和冗余作用,并鉴定新的药物在子宫,卵巢,卵巢,肌肉,肌肉,肌肉学中抑制和/或模仿BMPS,激活素和肌蛋白酶的功能。这些提出的研究的具体目的是:1)定义植入和植入后子宫生物学中的BMP受体途径,以及2)识别和合成小分子BMP受体特异性拮抗剂和激动剂。这些提出的研究将使我们能够将TGF2超家族,受体和下游SMAD置于女性生殖道的生物途径中,并鉴定并合成化合物,以使未来的人类生殖和非促成疾病治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

MARTIN M. MATZUK的其他基金

Kinases as Therapeutic Targets for Endometriosis
激酶作为子宫内膜异位症的治疗靶点
  • 批准号:
    10674987
    10674987
  • 财政年份:
    2022
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
  • 批准号:
    10682061
    10682061
  • 财政年份:
    2022
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
  • 批准号:
    10764639
    10764639
  • 财政年份:
    2022
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
  • 批准号:
    10419647
    10419647
  • 财政年份:
    2022
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
  • 批准号:
    10598585
    10598585
  • 财政年份:
    2022
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Kinases as Therapeutic Targets for Endometriosis
激酶作为子宫内膜异位症的治疗靶点
  • 批准号:
    10532966
    10532966
  • 财政年份:
    2022
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Targeting testis-specific ubiquitin-proteasome pathways for male contraception
针对男性避孕的睾丸特异性泛素蛋白酶体途径
  • 批准号:
    10018522
    10018522
  • 财政年份:
    2019
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Functional genomics and DEC-Tec to identify germ cell-specific contraceptives
功能基因组学和 DEC-Tec 鉴定生殖细胞特异性避孕药
  • 批准号:
    10164823
    10164823
  • 财政年份:
    2017
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9278437
    9278437
  • 财政年份:
    2017
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10164824
    10164824
  • 财政年份:
    2017
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:

相似海外基金

Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
  • 批准号:
    8495780
    8495780
  • 财政年份:
    1994
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
  • 批准号:
    8324763
    8324763
  • 财政年份:
    1994
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
  • 批准号:
    8791403
    8791403
  • 财政年份:
    1994
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
  • 批准号:
    8291137
    8291137
  • 财政年份:
    1994
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别:
Bone Morphogenic Protein Signaling Pathways in Uterine Biology
子宫生物学中的骨形态发生蛋白信号通路
  • 批准号:
    8150354
    8150354
  • 财政年份:
    1994
  • 资助金额:
    $ 38.49万
    $ 38.49万
  • 项目类别: